Iowa State University College of Veterinary Medicine to Conduct a Study with Immunocidin® Equine in Two Types of Cancer
NovaVive's Immunocidin® Equine anticancer immunotherapeutic for horses will be evaluated in a clinical study at Iowa State University (ISU) College of Veterinary Medicine in sarcoids and squamous cell carcinoma.
Settle®, an Antibiotic Alternative for Treating Equine Endometritis, is Now Approved for Sale in New Zealand
NovaVive's immunotherapeutic for the treatment of equine endometritis, Settle®, has been approved for sale to New Zealand veterinarians by the NZ regulator. It was previously approved for sale in the U.S. and Australia.
Equine Sarcoid Tumor Product Now Available to Canadian Veterinarians
An equine-specific version of Immunocidin® for equine sarcoid tumors is now available to Canadian veterinarians. The new product, Immunocidin® Equine, is packaged in 5mL vials and is approved by the Canadian regulator (CFIA).
Equine Sarcoid Tumor Product Now Available to U.S. Veterinarians
NovaVive now offers an equine-specific version of its Immunocidin® product for equine sarcoids in response to demand by U.S. veterinarians. Immunocidin® Equine is packaged in 5mL vials for the convenience of practitioners.
Settle®: A Regulator-Approved Antibiotic Alternative for Treating Equine Endometritis
NovaVive offers an alternative to antibiotics for the treatment of equine endometritis: Settle®. This product is fully approved by regulators in the U.S. and Australia for endometritis caused by Streptococcus zooepidemicus.
U.S. and Canadian Regulator-Approved Immunotherapeutic Available for Equine Sarcoid Tumors
NovaVive's cancer immunotherapy, Immunocidin(R), received USDA and CFIA approval for the treatment of equine sarcoid tumors in February, 2016. The Company believes that this is North America's first approved sarcoid therapy.